Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Australia.
J Hematol Oncol. 2008 Jul 29;1:10. doi: 10.1186/1756-8722-1-10.
Molecular characterisation of normal karyotype acute myeloid leukemia (NK-AML) allows prognostic stratification and potentially can alter treatment choices and pathways. Approximately 45-60% of patients with NK-AML carry NPM1 gene mutations and are associated with a favourable clinical outcome when FLT3-internal tandem duplications (ITD) are absent. High resolution melting (HRM) is a novel screening method that enables rapid identification of mutation positive DNA samples.
We developed HRM assays to detect NPM1 mutations and FLT3-ITD and tested diagnostic samples from 44 NK-AML patients. Eight were NPM1 mutation positive only, 4 were both NPM1 mutation and FLT3-ITD positive and 4 were FLT3-ITD positive only. A novel point mutation Y572C (c.1715A>G) in exon 14 of FLT3 was also detected. In the group with de novo NK-AML, 40% (12/29) were NPM1 mutation positive whereas NPM1 mutations were observed in 20% (3/15) of secondary NK-AML cases. Sequencing was performed and demonstrated 100% concordance with the HRM results.
HRM is a rapid and efficient method of screening NK-AML samples for both novel and known NPM1 and FLT3 mutations. NPM1 mutations can be observed in both primary and secondary NK-AML cases.
正常核型急性髓系白血病(NK-AML)的分子特征可进行预后分层,并且可能改变治疗选择和途径。大约 45-60%的 NK-AML 患者携带 NPM1 基因突变,并且在不存在 FLT3 内部串联重复(ITD)时与良好的临床结果相关。高分辨率熔解(HRM)是一种新型的筛选方法,可快速识别突变阳性的 DNA 样本。
我们开发了 HRM 检测 NPM1 突变和 FLT3-ITD 的检测方法,并测试了 44 例 NK-AML 患者的诊断样本。其中 8 例仅为 NPM1 突变阳性,4 例为 NPM1 突变和 FLT3-ITD 均阳性,4 例仅为 FLT3-ITD 阳性。还检测到 FLT3 外显子 14 中的新型点突变 Y572C(c.1715A>G)。在新发 NK-AML 组中,40%(29 例中的 12 例)为 NPM1 突变阳性,而继发性 NK-AML 病例中仅观察到 20%(15 例中的 3 例)存在 NPM1 突变。进行了测序,与 HRM 结果完全一致。
HRM 是一种快速有效的筛选 NK-AML 样本中新型和已知 NPM1 和 FLT3 突变的方法。原发性和继发性 NK-AML 病例中均可观察到 NPM1 突变。